Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.
Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology.
Ploussard G, et al.
Urol Oncol. 2015 Feb;33(2):71.e1-9. doi: 10.1016/j.urolonc.2014.07.007. Epub 2014 Aug 15.
Urol Oncol. 2015.
PMID: 25131660